A new study released in Cell Reports found a common gut bacterium that boosts digestive health may also help guard against Parkinson disease.
A new study published in Cell Reports found a common gut bacterium that boosts digestive health may also help guard against Parkinson disease (PD).
The probiotic Bacillus subtilis strain PXN21 can slow and even reverse build-up of the protein α-synuclein, which is associated with PD. In the brains of patients with PD, α-synuclein “misfolds and builds up, forming toxic clumps. These clumps are associated with the death of nerve cells responsible for producing dopamine. The loss of these cells causes the motor symptoms associated with Parkinson's, including freezing, tremors, and slowness of movement,” according to the study's researchers.
The study was conducted on roundworms altered to produce the human version of α-synuclein. Bacillus subtilis, when introduced in the roundworms, was effective in protecting against build-up of the harmful α-synuclein protein and was able to clear formed protein clumps. As a result, movement symptoms associated with PD improved in the roundworms. The researchers also found, “The bacteria was able to prevent the formation of toxic α-synuclein clumps by producing chemicals that change how enzymes in cells process specific fats called sphingolipids.”
The encouraging outcomes prompted the researchers to suggest the next steps of confirming results in mice, followed by clinical trials. They say the probiotic is already commercially available, which means clinical trials can be fast-tracked.
Previous studies have documented how fecal transplants from patients with PD to mouse models exacerbated symptoms of PD, suggesting differences in microbiota can impact the disease’s progression and are not merely a result of PD, as well as shown that PD symptoms and α-synuclein pathology begin in peripheral tissues, specifically the intestine, and that as the disease progresses, the protein aggregates spread to brain regions.
“Preclinical evidence suggests that the gut microbiota and intestinal permeability modulate behavior, mood, and neuropsychiatric disorders,” researchers have noted.
PD is one of the most prevalent neurodegenerative disorders in the world, and currently there is no cure. The research manager at Parkinson’s UK, Beckie Port, PhD, said of the results, “Studies that identify bacteria that are beneficial in Parkinson's have the potential to not only improve symptoms but could even protect people from developing the condition in the first place.” Parkinson’s UK funded the Cell Reports study.
Reference
Goya ME, Xue F, Sampedro-Torres-Quevedo C, et al. Probiotic Bacillus Subtilis protects against a-synuclein aggregation in C. Elegans. Cell Rep. 2020;30(2):367-380. doi: 10.1016/j.celrep.2019.12.078.
Dr Chakra Chaulagain: PFS Is the "Bare Minimum," but OS Is Ideal for Choosing Between MM Therapies
March 28th 2024Response rates are important when choosing between therapies to treat multiple myeloma (MM), but improvement overall survival (OS) is the ideal, said Chakra Chaulagain MD, FACP, hematologist/oncologist, Maroone Cancer Center of Cleveland Clinic Florida.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Alopecia Areata Impacts Patient Perception, Quality of Life
March 27th 2024Patients with alopecia areata (AA) often perceive their hair loss as more severe than dermatologists do, leading to increased emotional and social problems. This study highlights the importance of understanding patient perception for better treatment and improved quality of life.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More